Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2022-12-22 00:00:00 ET · period of report 2022-12-21 · accession 0001104659-22-129348 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-22 | 2022-12-21 | NVCT | Shemesh Shay | Chief Dev, Ops. Off | P - Purchase | $7.65 | +500 | 1.25M | +0.0% | +$3,825 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-21 | P | A | 500 | $7.65 | 1,245,865 | D | — | — | (F1) Reflects the weighted average purchase price. The range of prices for the shares purchased was $7.595 to $7.7514. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. (F2) Includes 48,399 shares of restricted stock and 60,000 restricted stock units. |